Latest News

Vibostolimab/Pembrolizumab Fails to Reach Statistical Significance in NSCLC
Vibostolimab/Pembrolizumab Fails to Reach Statistical Significance in NSCLC

December 8th 2023

The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.

Merck Halts Phase 3 Pembrolizumab/Olaparib Trial in NSCLC
Merck Halts Phase 3 Pembrolizumab/Olaparib Trial in NSCLC

December 7th 2023

Case-Based Format Spotlights Hawaii Lung Cancer Conference
Case-Based Format Spotlights Hawaii Lung Cancer Conference

December 7th 2023

Discussing Response of Amivantamab in EGFR Exon 20+ NSCLC
Discussing Response of Amivantamab in EGFR Exon 20+ NSCLC

December 4th 2023

Video Series
Video Interviews
Podcasts

More News